Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Instagram Outage Disrupts Thousands of U.S. Users 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
PORT WASHINGTON, N.Y., April 07, 2016 -- ACETO Corporation (NASDAQ:ACET), an international company engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Salvatore Guccione, President and CEO, will present at the Needham & Company Healthcare Conference on April 12, 2016 at 5:00 pm ET at the Westin New York Grand Central Hotel.
A webcast of the presentation will be available under Events and Presentations in the investor relations section of the company’s website at www.aceto.com or http://wsw.com/webcast/needham76/acet.
ABOUT ACETO
ACETO Corporation, incorporated in 1947 and with offices and operations in 10 countries, is engaged in the marketing, sale and distribution of Human Health products (finished dosage form generics and nutritional products), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical ingredients) and Performance Chemicals (specialty chemicals and agricultural protection products).
Investor Relations Contact: LHA Jody Burfening [email protected] (212) 838-3777
